[Severe hyponatraemia secondary to cure of cyclophosphamide (about three cases)].
Alilou
M
M
Awab
A
A
Zarouf
M
M
Moussaoui
R El
RE
Hijri
A El
AE
Azzouzi
A
A
Slaoui
A
A
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000150:complications; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced* / Q000188:drug therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007177:Inappropriate ADH Syndrome / Q000139:chemically induced; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged
D018906:Antineoplastic Agents, Alkylating; D004232:Diuretics; D007166:Immunosuppressive Agents; D005665:Furosemide; D003520:Cyclophosphamide